Advertisement

Topics

Kalytera scraps pre-clinical programs in bone disease

05:09 EDT 16 Apr 2018 | Pharmaceutical Business Review

Kalytera Therapeutics has announced the termination of its pre-clinical development programs in the treatment of bone disease to focus its resources on graft versus host disease (GVHD) and pain programs.

Original Article: Kalytera scraps pre-clinical programs in bone disease

NEXT ARTICLE

More From BioPortfolio on "Kalytera scraps pre-clinical programs in bone disease"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pain
Pain is defined by the International Association for the Study of Pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage”. Some illnesses can be excruci...